BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38580170)

  • 1. Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp.
    Wong G; Bienes KM; Xiii A; Fausther-Bovendo H; Kobinger GP
    Antiviral Res; 2024 Jun; 226():105873. PubMed ID: 38580170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.
    Qiu X; Wong G; Audet J; Bello A; Fernando L; Alimonti JB; Fausther-Bovendo H; Wei H; Aviles J; Hiatt E; Johnson A; Morton J; Swope K; Bohorov O; Bohorova N; Goodman C; Kim D; Pauly MH; Velasco J; Pettitt J; Olinger GG; Whaley K; Xu B; Strong JE; Zeitlin L; Kobinger GP
    Nature; 2014 Oct; 514(7520):47-53. PubMed ID: 25171469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of monoclonal antibodies for the treatment of Ebola virus disease.].
    Sizikova TE; Borisevich GV; Shcheblyakov DV; Burmistrova DA; Lebedev VN
    Vopr Virusol; 2018; 63(6):245-249. PubMed ID: 30641019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
    Tshiani Mbaya O; Mukumbayi P; Mulangu S
    Front Immunol; 2021; 12():721328. PubMed ID: 34526994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
    Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
    Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ongoing evolution of antibody-based treatments for Ebola virus infection.
    Mendoza EJ; Racine T; Kobinger GP
    Immunotherapy; 2017 Mar; 9(5):435-450. PubMed ID: 28357917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobacco against Ebola virus disease.
    Budzianowski J
    Przegl Lek; 2015; 72(10):567-71. PubMed ID: 26946569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.
    Bornholdt ZA; Turner HL; Murin CD; Li W; Sok D; Souders CA; Piper AE; Goff A; Shamblin JD; Wollen SE; Sprague TR; Fusco ML; Pommert KB; Cavacini LA; Smith HL; Klempner M; Reimann KA; Krauland E; Gerngross TU; Wittrup KD; Saphire EO; Burton DR; Glass PJ; Ward AB; Walker LM
    Science; 2016 Mar; 351(6277):1078-83. PubMed ID: 26912366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop.
    Banadyga L; Zhu W; Kailasan S; Howell KA; Franaszek K; He S; Siragam V; Cheng K; Yan F; Moffat E; Cao W; Leung A; Embury-Hyatt C; Aman MJ; Qiu X
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structures of protective antibodies reveal sites of vulnerability on Ebola virus.
    Murin CD; Fusco ML; Bornholdt ZA; Qiu X; Olinger GG; Zeitlin L; Kobinger GP; Ward AB; Saphire EO
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17182-7. PubMed ID: 25404321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ebola virus-induced eye sequelae: a murine model for evaluating glycoprotein-targeting therapeutics.
    Lee HN; Xu B; Lewkowicz AP; Engel K; Kelley-Baker L; McWilliams IL; Ireland DDC; Kielczewski JL; Li J; Fariss RN; Campos MM; Baum A; Kyratsous C; Pascal K; Chan CC; Caspi RR; Manangeeswaran M; Verthelyi D
    EBioMedicine; 2024 Jun; 104():105170. PubMed ID: 38823088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
    Murin CD; Gilchuk P; Crowe JE; Ward AB
    Front Immunol; 2021; 12():808047. PubMed ID: 35082794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cocktail party: Low-dose antibody combinations deliver pan-ebolavirus protection.
    Anthony SM; Hensley LE
    Cell; 2022 Mar; 185(6):943-945. PubMed ID: 35303426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
    Tran EE; Nelson EA; Bonagiri P; Simmons JA; Shoemaker CJ; Schmaljohn CS; Kobinger GP; Zeitlin L; Subramaniam S; White JM
    J Virol; 2016 Sep; 90(17):7618-27. PubMed ID: 27279622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
    Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
    Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A glimpse into immune responses evolving against Ebola virus.
    Saphire EO
    Nat Med; 2019 Oct; 25(10):1470-1471. PubMed ID: 31591604
    [No Abstract]   [Full Text] [Related]  

  • 20. A review of broadly protective monoclonal antibodies to treat Ebola virus disease.
    Rijal P; Donnellan FR
    Curr Opin Virol; 2023 Aug; 61():101339. PubMed ID: 37392670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.